The OPTIFAST total and partial meal replacement programme reduces cardiometabolic risk in adults with obesity: Secondary and exploratory analysis of the OPTIWIN study

Author:

Ard Jamy D.1,Neeland Ian J.2,Rothberg Amy E.3,Chilton Robert J.4,de Luis Daniel5,Cohen Sarah S.6,Johansen Odd Erik7ORCID

Affiliation:

1. Wake Forest School of Medicine Winston‐Salem North Carolina USA

2. Harrington Heart and Vascular Institute, University Hospitals Cleveland Medical Center Case Western Reserve University School of Medicine Cleveland Ohio USA

3. University of Michigan Ann Arbor Michigan USA

4. University of Texas Health Science Center San Antonio Texas USA

5. Center of Investigation of Endocrinlogy and Nutrition University of Valladolid, Hospital clínico Universitario de Valladolid Valladolid Spain

6. EpidStrategies, A Division of Tox Strategies Inc. Katy Texas USA

7. Nestlé Health Science Lausanne Switzerland

Abstract

AbstractAimThe effects of weight loss with a partial or total meal replacement programme (MRP) on atherosclerotic cardiovascular disease (ASCVD) risk factors are not fully understood, in particular in people at higher CV risk. In the 52‐week randomized controlled OPTIWIN study in men and women with obesity, meal replacement programme (total for first 26 weeks, partial for the ensuing 26 weeks) with OPTIFAST (OP) resulted in significantly greater weight loss compared with a low‐calorie food‐based (FB) dietary plan, both as part of a comprehensive lifestyle intervention [OP (n = 135)/FB (n = 138) week 26: −12.4%/−6.0%, p < .001; week 52: −10.5%/−5.5%, p < .001]. Here, we examined effects on ASCVD risk factors and 10‐year ASCVD risk.Materials and MethodsParticipants with body mass index 30‐55 kg/m2 and age 18‐70 years, and not on anti‐obesity medications, were recruited. The effects on systolic and diastolic blood pressure (SBP, DBP), lipid parameters and 10‐year ASCVD risk were analysed as changes over time using linear mixed models. Subgroup analyses were conducted for changes in SBP, DBP and ASCVD risk by categories of age (<40, 40‐59, ≥60 years), baseline SBP (</≥130 mmHg) and sex.ResultsBaseline characteristics were well balanced (OP/FB females 86%/79%, mean age 47/47 years, body mass index 38.4/39.2 kg/m2, 10‐year ASCVD risk <5% 87%/74%, dysglycaemia 52%/50%). At week 26, SBP/DBP were significantly reduced with OP versus FB, and a greater proportion achieved BP ≤130/80 mmHg [odds ratio 2.11 (95% confidence interval 1.10, 4.03), p = .024]. All lipid parameters as well as 10‐year ASCVD risk were significantly improved with OP versus FB. A similar, but slightly attenuated pattern was observed at 52 weeks. Across subgroups, greater reductions for SBP, DBP and ASCVD risk were generally seen with OP versus FB with quantitatively higher baseline SBP and age, and in men.ConclusionsIn people with obesity at low ASCVD risk, OP significantly reduced cardiovascular risk factors and 10‐year predicted risk for ASCVD.

Funder

Nestlé Health Science

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3